Pharma CEOs Dish on the Trump Effect
Top execs from large U.S. drug companies discussed what the pharma future holds under President-elect Donald Trump, and comment on pricing issues that have cast a shadow on the industry.
Trump has said he wants to repeal Obamacare and reform Medicare and Medicaid, but he has not addressed the companies that have come under fire recently because of huge drug price increases.
Pharma companies are relieved, but Trump could be more critical of drugmakers and their price increases than the industry expects, says Allergan Inc CEO Brent Saunders, in a Reuters article.
Read the story for more pharma predictions